Cushman & Wakefield sees U.S. life sciences real estate market rebalancing as development slows

• Cushman & Wakefield flagged a gradual rebalancing in U.S. life sciences real estate as new development slows, despite elevated vacancy.
• Q2 2026 asking rents averaged $64.17 psf, down 2.2% QOQ, down 5.3% YOY; still 37% above traditional office.
• Vacancy rose to 24.3% in Q2 2026 from 23.4% at end-2025; sublease vacancy eased to 3.4%.
• Pipeline fell below 6 msf under construction, or 2% of inventory, versus 35 msf in 2023; 4.4 msf delivers through 2027, 69% preleased.
• R&D sales volume reached $9.3 billion over four quarters through Q2 2026, up 4% YOY; life sciences VC funding topped $17.7 billion in H1 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cushman & Wakefield Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608311631BIZWIRE_USPR_____20260831_BW912875) on August 31, 2026, and is solely responsible for the information contained therein.